Goldman Sachs Group Inc Regenxbio Inc. Transaction History

Goldman Sachs Group Inc

$780 Billion
Q3 2025

A detailed history of Goldman Sachs Group Inc transactions in Regenxbio Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 1,852,214 shares of RGNX stock, worth $21.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares

1,852,214

Previous 1,784,506 3.79%

Holding current value

$21.3 Million

Previous $14.7 Million 22.0%

% of portfolio

0.0%

Previous 0.0%

23 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2025 Nov 14, 2025	BUY	$7.46 - $9.89 $505,101 - $669,632	67,708 Added 3.79%	1,852,214 $17.9 Million
Q2 2025 Aug 14, 2025	BUY	$5.31 - $10.4 $5.48 Million - $10.7 Million	1,031,779 Added 137.07%	1,784,506 $14.7 Million
Q1 2025 May 09, 2025	SELL	$5.92 - $8.7 $20,785 - $30,545	-3,511 Reduced 0.46%	752,727 $5.38 Million
Q4 2024 Feb 11, 2025	BUY	$7.23 - $11.56 $92,912 - $148,557	12,851 Added 1.73%	756,238 $5.85 Million
Q3 2024 Nov 14, 2024	BUY	$10.49 - $14.39 $987,570 - $1.35 Million	94,144 Added 14.5%	743,387 $7.8 Million
Q2 2024 Aug 13, 2024	SELL	$11.51 - $21.53 $855,906 - $1.6 Million	-74,362 Reduced 10.28%	649,243 $7.6 Million
Q1 2024 May 15, 2024	BUY	$12.17 - $24.61 $4.72 Million - $9.54 Million	387,499 Added 115.29%	723,605 $15.2 Million
Q4 2023 Feb 13, 2024	SELL	$12.89 - $20.82 $3.36 Million - $5.43 Million	-260,748 Reduced 43.69%	336,106 $6.03 Million
Q3 2023 May 14, 2024	BUY	$16.46 - $19.99 $4.29 Million - $5.21 Million	260,748 Added 77.58%	596,854 $9.82 Million
Q3 2023 Nov 14, 2023	BUY	$16.46 - $19.99 $277,762 - $337,331	16,875 Added 2.91%	596,854 $9.82 Million
Q2 2023 May 14, 2024	BUY	$17.23 - $21.71 $400,907 - $505,148	23,268 Added 4.18%	579,979 $11.6 Million
Q2 2023 Aug 14, 2023	BUY	$17.23 - $21.71 $400,907 - $505,148	23,268 Added 4.18%	579,979 $11.6 Million
Q1 2023 May 14, 2024	SELL	$18.08 - $24.55 $718,806 - $976,034	-39,757 Reduced 6.67%	556,711 $10.5 Million
Q1 2023 May 11, 2023	SELL	$18.08 - $24.55 $718,806 - $976,034	-39,757 Reduced 6.67%	556,711 $10.5 Million
Q4 2022 May 14, 2024	SELL	$20.4 - $24.73 $707,778 - $858,007	-34,695 Reduced 5.5%	596,468 $13.5 Million
Q4 2022 Feb 13, 2023	SELL	$20.4 - $24.73 $707,778 - $858,007	-34,695 Reduced 5.5%	596,468 $13.5 Million
Q3 2022 May 14, 2024	BUY	$22.29 - $35.04 $2.92 Million - $4.59 Million	131,038 Added 26.2%	631,163 $16.7 Million
Q3 2022 Nov 10, 2022	BUY	$22.29 - $35.04 $2.92 Million - $4.59 Million	131,038 Added 26.2%	631,163 $16.7 Million
Q2 2022 May 14, 2024	BUY	$19.35 - $35.04 $3.17 Million - $5.75 Million	164,019 Added 48.8%	500,125 $12.4 Million
Q2 2022 Aug 15, 2022	BUY	$19.35 - $35.04 $7.37 Million - $13.4 Million	381,047 Added 320.0%	500,125 $12.4 Million
Q1 2022 May 16, 2022	SELL	$24.62 - $34.31 $4.94 Million - $6.88 Million	-200,469 Reduced 62.74%	119,078 $3.95 Million
Q4 2021 Feb 14, 2022	SELL	$30.19 - $40.28 $1.71 Million - $2.29 Million	-56,795 Reduced 15.09%	319,547 $10.4 Million
Q3 2021 Nov 10, 2021	BUY	$29.09 - $45.68 $10.9 Million - $17.2 Million	376,342 New	376,342 $15.8 Million

Others Institutions Holding RGNX

# of Institutions

187

Shares Held

44.5M

Call Options Held

138K

Put Options Held

117K

View Full List

About REGENXBIO Inc.

Ticker RGNX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,230,000
Market Cap $498M
Description
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprie...

More about RGNX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Account

Goldman Sachs Group Inc Regenxbio Inc. Transaction History